SEC Gets Consent Win For CEO's COVID-19 Product Claims
The U.S. Securities and Exchange Commission's case against a biotechnology firm and its chief executive accused of falsely claiming regulators approved of their disinfectants for fighting COVID-19 has resulted in a...To view the full article, register now.
Already a subscriber? Click here to view full article